JP2008525476A5 - - Google Patents

Download PDF

Info

Publication number
JP2008525476A5
JP2008525476A5 JP2007548472A JP2007548472A JP2008525476A5 JP 2008525476 A5 JP2008525476 A5 JP 2008525476A5 JP 2007548472 A JP2007548472 A JP 2007548472A JP 2007548472 A JP2007548472 A JP 2007548472A JP 2008525476 A5 JP2008525476 A5 JP 2008525476A5
Authority
JP
Japan
Prior art keywords
cyclopropa
tetrahydro
diaza
pentalene
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007548472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008525476A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/046599 external-priority patent/WO2006069242A2/en
Publication of JP2008525476A publication Critical patent/JP2008525476A/ja
Publication of JP2008525476A5 publication Critical patent/JP2008525476A5/ja
Withdrawn legal-status Critical Current

Links

JP2007548472A 2004-12-23 2005-12-22 代謝関連障害の処置法における縮合ピラゾール誘導体およびその使用 Withdrawn JP2008525476A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63866804P 2004-12-23 2004-12-23
US67652105P 2005-04-29 2005-04-29
PCT/US2005/046599 WO2006069242A2 (en) 2004-12-23 2005-12-22 Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related?disorders

Publications (2)

Publication Number Publication Date
JP2008525476A JP2008525476A (ja) 2008-07-17
JP2008525476A5 true JP2008525476A5 (cg-RX-API-DMAC7.html) 2009-02-12

Family

ID=36593187

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007548472A Withdrawn JP2008525476A (ja) 2004-12-23 2005-12-22 代謝関連障害の処置法における縮合ピラゾール誘導体およびその使用

Country Status (24)

Country Link
US (3) US7241792B2 (cg-RX-API-DMAC7.html)
EP (1) EP1831178A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008525476A (cg-RX-API-DMAC7.html)
KR (1) KR20070088808A (cg-RX-API-DMAC7.html)
CN (2) CN102311378A (cg-RX-API-DMAC7.html)
AR (1) AR055015A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005319121A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0519262A2 (cg-RX-API-DMAC7.html)
CA (1) CA2589648A1 (cg-RX-API-DMAC7.html)
CU (1) CU23691B7 (cg-RX-API-DMAC7.html)
EA (1) EA013184B1 (cg-RX-API-DMAC7.html)
GE (1) GEP20105126B (cg-RX-API-DMAC7.html)
GT (1) GT200500379A (cg-RX-API-DMAC7.html)
HN (1) HN2005036256A (cg-RX-API-DMAC7.html)
IL (1) IL183654A0 (cg-RX-API-DMAC7.html)
MA (1) MA29148B1 (cg-RX-API-DMAC7.html)
NI (1) NI200700161A (cg-RX-API-DMAC7.html)
NO (1) NO20073766L (cg-RX-API-DMAC7.html)
NZ (1) NZ555721A (cg-RX-API-DMAC7.html)
PA (1) PA8658301A1 (cg-RX-API-DMAC7.html)
PE (1) PE20060949A1 (cg-RX-API-DMAC7.html)
TN (1) TNSN07236A1 (cg-RX-API-DMAC7.html)
TW (1) TW200635904A (cg-RX-API-DMAC7.html)
WO (1) WO2006069242A2 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
ES2331521T3 (es) 2003-11-21 2010-01-07 Arena Pharmaceuticals, Inc. Derivados de acido 4-oxo-4,5-dihidro-furan-2-carboxilico y procedimientos de tratamiento de trastornos metabolicos relacionados del mismo.
PE20060949A1 (es) * 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CA2611552A1 (en) 2005-06-28 2007-01-04 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2470508A1 (en) * 2009-08-28 2012-07-04 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012116278A1 (en) * 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
MX392150B (es) * 2011-02-25 2025-03-21 Arena Pharm Inc Moduladores de receptores canabinoides.
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
JP5945554B2 (ja) 2011-02-25 2016-07-05 アリーナ ファーマシューティカルズ, インコーポレイテッド 縮合型アザ環の結晶形およびその調製プロセス(カンナビノイド受容体モジュレーター)
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US20200078358A1 (en) 2017-05-08 2020-03-12 Arena Pharmaceuticals, Inc. Compounds and Methods for Treatment of Visceral Pain
BR112021002207A2 (pt) 2018-08-10 2021-05-04 Diapin Therapeutics, Llc tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105336A (en) * 1961-05-16 1963-10-01 Package Machinery Co Converting wrapping machines to wrap different size articles
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US5134155A (en) 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
DE69935335T2 (de) * 1998-08-07 2007-11-22 Novartis Vaccines and Diagnostics, Inc., Emeryville Pyrazole als modulatoren des östrogenrezeptors
KR20030010589A (ko) 2000-03-09 2003-02-05 오노 야꾸힝 고교 가부시키가이샤 인돌 유도체, 그 제조 방법 및 용도
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
DE60215000T2 (de) 2001-05-23 2007-08-09 Merck Frosst Canada & Co, Kirkland Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten
JP3968076B2 (ja) 2001-06-27 2007-08-29 アールエス テック コーポレイション 新しいキラルサレン化合物、キラルサレン触媒及びこれを利用したラセミックエポキシ化合物からキラル化合物を製造する方法
EP1424335A4 (en) 2001-09-07 2005-11-16 Ono Pharmaceutical Co INDOLE DERIVATIVES
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
CN100378083C (zh) 2002-03-19 2008-04-02 小野药品工业株式会社 羧酸化合物和含有所述化合物作为活性成分的药物制剂
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
US20060167270A1 (en) * 2002-10-10 2006-07-27 Arena Pharmaceuticals Inc. 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
CA2528834A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
GB0319126D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
TWI258478B (en) * 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
CA2556073C (en) 2004-02-14 2012-01-10 Smithkline Beecham Corporation 8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators
PE20060949A1 (es) * 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina

Similar Documents

Publication Publication Date Title
AU2003300967B2 (en) Substituted amides
MXPA06001636A (es) Antagonista del receptor de la hormona concentradora de melanina.
JP6624594B2 (ja) 炎症性、代謝性、腫瘍性および自己免疫疾患の処置に有用なピリミジンの任意選択により縮合されているヘテロシクリル置換誘導体
TNSN07236A1 (en) Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related disorders
HUE028051T2 (hu) Neprilizin inhibitorok
CA2598536A1 (en) Oxyindole derivatives as 5ht4 receptor agonists
TWI659950B (zh) 作為硝醯基予體之吡唑啉酮衍生物
EA011935B1 (ru) Производные 3-фенилпиразола в качестве модуляторов 5-htсеротонинового рецептора, полезные для лечения расстройств, связанных с этим рецептором
KR20160033726A (ko) 헤테로방향족 고리-벤질-아미드-사이클 코어를 포함하는 오토탁신 억제제
JP2003505384A (ja) ブラジキニンb1受容体アンタゴニスト
WO2016021742A1 (en) Heterocyclic compounds as ep4 receptor antagonists
CN101166721A (zh) 具有pgd2拮抗剂活性的1-乙酸-吲哚衍生物
RU2009138219A (ru) Новые бензамидные производные и способ их получения
IL179599A0 (en) Glucagon receptor antagonists, preparation and therapeutic uses
JP2005272321A (ja) 含窒素複素環化合物およびその医薬用途
TW201031638A (en) 4-aryl-butane-1,3-diamides
JPH0748360A (ja) ビフェニルテトラゾール誘導体
JP2008534457A (ja) 高血圧症処置用の3,4−置換ピロリジン誘導体
KR101923365B1 (ko) Crth2 길항제로서의 피라졸 화합물들
HUE027252T2 (en) Benzazole derivatives as histamine H4 receptor ligands
JP2004507527A5 (cg-RX-API-DMAC7.html)
JP5537159B2 (ja) 3位置換スルホニルピペリジン誘導体
CA2539985A1 (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US20230086179A1 (en) Carboxylic acid aromatic amides
JP2012505226A5 (cg-RX-API-DMAC7.html)